2024 World Conference on Lung Cancer (WCLC) - Posters-P1.12A.05 Aumolertinib in Treatment-Naïve EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY

P1.12A.05 Aumolertinib in Treatment-Naïve EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY

Back to course

Pdf Summary

The ARTISTRY study is evaluating the use of aumolertinib, a third-generation EGFR-TKI, for treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC) patients with brain metastases. This is especially relevant as third-generation TKIs have shown improved efficacy over first-generation options in previous trials like FLAURA and AENEAS. The latest analysis focuses on cohort 1, patients with brain parenchymal metastases, assessing both efficacy and safety outcomes.<br /><br />At the time of data cut-off on March 15, 2024, 26 patients were part of this study with a median follow-up of 17.8 months. Two dosing levels were tested: 110mg and 165mg. In the 110mg cohort, the objective response rate (ORR) was 88.46%, and the disease control rate (DCR) was 96.15%, with a median progression-free survival (PFS) of 18.5 months. This indicates strong antitumor activity and manageable safety—with some patients experiencing lung lesion progression while retaining partial responses in brain metastases. The 165mg cohort had a median PFS of 7.37 months, demonstrating less efficacy with an iORR of 20%.<br /><br />Aumolertinib appears to offer substantial benefits as a first-line treatment for EGFR-mutant NSCLC patients with brain metastases, and it remains effective even with disease progression in other areas. Future research aims to verify its long-term outcomes and continue assessing the optimal therapeutic windows and doses. The study appreciates the contributions of patients, their families, the researchers, and other support staff, and is supported by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Asset Subtitle

Xiaojuan Zhang

Meta Tag

Speaker Xiaojuan Zhang

Topic Metastatic NSCLC – Targeted Therapy

Keywords

ARTISTRY study

aumolertinib

EGFR-TKI

non-small cell lung cancer

brain metastases

third-generation TKIs

FLAURA trial

AENEAS trial

objective response rate

progression-free survival